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Toxicity of overexpressed MeCP2
is independent of HDAC3 activity
MarthaV. Koerner,1 Laura FitzPatrick,1 Jim Selfridge,1 JackyGuy,1 DinaDe Sousa,1 RebekahTillotson,1
Alastair Kerr,1 Zheng Sun,2,3 Mitchell A. Lazar,2 Matthew J. Lyst,1 and Adrian Bird1
1WellcomeCentre forCell Biology, University of Edinburgh, Edinburgh EH93BF,UnitedKingdom; 2Institute forDiabetes, Obesity,
and Metabolism, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104, USA
Duplication of the X-linkedMECP2 gene causes a severe neurological syndrome whose molecular basis is poorly
understood. To determine the contribution of known functional domains to overexpression toxicity, we engineered
amousemodel that expresseswild-type ormutatedMeCP2 from theMapt (Tau) locus in addition to the endogenous
protein. Animals that expressed approximately four times thewild-type level ofMeCP2 failed to survive toweaning.
Strikingly, a single amino acid substitution that prevents MeCP2 from binding to the TBL1X(R1) subunit of nuclear
receptor corepressor 1/2 (NCoR1/2) complexes, when expressed at equivalent high levels, was phenotypically in-
distinguishable from wild type, suggesting that excessive corepressor recruitment underlies toxicity. In contrast,
mutations affecting the DNA-binding domain were toxic when overexpressed. As the NCoR1/2 corepressors are
thought to act through histone deacetylation by histone deacetylase 3 (HDAC3), we asked whether mutations in
NCoR1 and NCoR2 that drastically reduced their ability to activate this enzyme would relieve the MeCP2 over-
expression phenotype. Surprisingly, severity was unaffected, indicating that the catalytic activity of HDAC3 is not
the mediator of toxicity. Our findings shed light on the molecular mechanisms underlyingMECP2 duplication
syndrome and call for a re-evaluation of the precise biological role played by corepressor recruitment.
[Keywords: histone deacetylase 3; MeCP2; NCoR]
Supplemental material is available for this article.
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Mutations involving the X-linked MECP2 gene cause an
array of human neurological disorders. Mosaicism for
severe deficiency of functional MeCP2 protein product
causes Rett syndrome, predominantly in females (Amir
et al. 1999), whereas excess protein causesMECP2 dupli-
cation syndrome, mostly affecting males (Van Esch et al.
2005). Molecular analysis of Rett syndromemissense mu-
tations, supported by equivalent genetic models in mice,
has identified two discrete regions of the protein within
which missense mutations are concentrated. These coin-
cide with and inactivate two domains in the MeCP2 pro-
tein thatwere identified in functional assays. Themethyl-
CpG-binding domain (MBD) binds to methylated sites in
DNA (Lewis et al. 1992; Nan et al. 1993), whereas the nu-
clear receptor corepressor (NCoR) interaction domain
(NID) interacts with a specific subunit—TBL1X(R1)—
that is shared by the NCoR1/2 corepressor complexes
(Lyst et al. 2013; Kruusvee et al. 2017). Accordingly,
mice retaining these two domains but lacking the re-
maining two thirds of the protein are fully viable, with rel-
atively mild phenotypic defects (Tillotson et al. 2017).
These and other data are compatible with the view that
MeCP2 functions primarily by recruiting the NCoR1/2
corepressors to methylated sites in the genome (Lyst and
Bird 2015). This scenario also agrees with evidence that
loss of MeCP2 leads to up-regulation of genes in propor-
tion to their MeCP2 occupancy in the wild-type mouse
brain (Kinde et al. 2016; Lagger et al. 2017).
As MeCP2 overexpression causes a disorder that is
clinically distinct from Rett syndrome, it is important to
establish whether toxicity is due to an excess of the
same two functional domains that are mutated in Rett
syndrome or whether other parts of the protein are in-
volved. A mouse model of overexpression has been creat-
ed by expressing the human MECP2 gene integrated as a
transgene in addition to the endogenous X-linked gene
(Collins et al. 2004). The resulting phenotype recapitu-
lates aspects of the human condition, although the pheno-
type is relatively mild. Creation of equivalent models
using MECP2 transgenes carrying missense mutations
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that interfere with either NID or MBD function failed to
register deleterious phenotypes, suggesting that these
two domains must be intact for overexpression to be det-
rimental (Heckman et al. 2014). To test this with in-
creased stringency, we used overexpression of the coding
region of MeCP2 from the autosomal Mapt (Tau) locus,
which achieves higher MeCP2 abundance and leads to a
severe phenotype. Luikenhuis et al. (2004) used thismeth-
od previously to show that mice lacking the endogenous
Mecp2 gene could be rescued by the Tau-MeCP2 fusion
protein expressed heterozygously but that high expression
in homozygous animals was severely detrimental. Ex-
tending this approach,we found that∼3.8-fold overexpres-
sion of MeCP2 is lethal in mice, but a missense mutation
in theNID exogenously expressed at a similarly high level
is benign. Our results emphasize that excess NID is an es-
sential mediator of overexpression toxicity. In contrast,
less extreme overexpression of hypomorphic MBD mu-
tants that cause Rett syndrome was deleterious, arguing
that the enhanced expression of these hypomorphic forms
ofMeCP2 in the presence of thewild-type proteinmay not
offer therapeutic benefit (Lamonica et al. 2017). As the
NID interacts with a shared subunit of theNCoR1/2 core-
pressors, it seemed plausible that overrecruitment might
cause excessive repression mediated by a catalytically ac-
tive component of these complexes: histone deacetylase
3 (HDAC3) (Guenther et al. 2001). To test this hypothesis
genetically, we asked whether toxicity associated with
overexpression ofMeCP2 inmice could be ameliorated by
mutation of the deacetylase activation domains (DADs) of
both NCoR1 and NCoR2 (You et al. 2013). Our results do
not support the hypothesis, as the phenotypes of mice
overexpressing MeCP2 were no less severe when the dou-
ble-DAD mutation was introduced into these animals.
Our results suggest that other aspects of corepressor func-
tion, distinct from HDAC3 activity, are deleterious when
excessive. Thus, while underlining the importance of the
NID as the primary underlying cause of MECP2 duplica-
tion syndrome, the findings raise questions about down-
stream mechanisms that mediate this effect.
Results
MeCP2 is expressed from the Tau locus at wild-type
levels in neurons and glia
In order to create a model of MECP2 duplication syn-
drome, we chose to replace the endogenous Tau-coding
region with an Mecp2 cDNA using constructs similar
to those described previously (Fig. 1A; Luikenhuis et al.
2004). Specifically, we inserted a cDNA encoding the en-
tire e2 isoform of MeCP2 in-frame downstream from the
N-terminal 31 codons of the Tau-coding region (Supple-
mental Fig. S1A–D). Western blot assays of MeCP2 in
Tau-Mecp2 heterozygote brains confirmed similar ex-
pression levels of Tau-MeCP2 and the slightly shorter
wild-type MeCP2 (Fig. 1B,C). Although Tau was initially
thought to be a neuron-specific protein, it is also expressed
at lower levels in glia (LoPresti et al. 1995). Accordingly,
MeCP2 expression derived from the Tau-Mecp2 recom-
bined locus was detected by flow cytometry of both neu-
ronal (NeuN-high) and glial (NeuN-low) nuclei in mice
lacking an endogenous Mecp2 gene (Fig. 1D). The wild-
type pattern of high MeCP2 levels in neurons and lower
levels in nonneuronal cells was recapitulated in mouse
brains heterozygous for Tau-Mecp2 on an Mecp2−/y
mouse background, although we noted slightly elevated
levels compared with wild-type in both cell types. Immu-
nostaining with an anti-MeCP2 antibody confirmed that
MeCP2 signal was abundant in Tau-Mecp2 neurons (Fig.
1E). We conclude that the expression profile of Mecp2
from a heterologous autosomal promoter and locus is re-
markably similar to that seen from the endogenous locus
in wild-type mice. Importantly, we confirmed a previous
report (Luikenhuis et al. 2004) that the Rett-like pheno-
types observed in Mecp2-null mice can be rescued by ex-
ogenous expression of MeCP2 from the Tau locus (Fig.
1F–H).
A 2.4-fold overexpression of MeCP2 is well tolerated,
but 3.8-fold overexpression is lethal
Having established that Tau-MeCP2 is expressed at appro-
priate levels and can phenotypically rescue Mecp2-null
mice, we asked whether overexpression gave a phenotype
that mimics MECP2 duplication syndrome. Mice wild
type for the endogenousMecp2 gene, but additionally ex-
pressing one Tau-Mecp2 allele, expressed, in total, ∼2.4
times wild-type levels of the protein (Fig. 1C). Remark-
ably, despite significant overexpression, these mice were
viable and fertile and survived for >1 yr (Fig. 2A–C). How-
ever, they exhibited reduced body weight, and we addi-
tionally noted a very late-onset (∼40 wk) breathing
phenotype manifest as “panting.” Further analysis using
the elevated plus maze, a test for anxiety, showed no dif-
ference in time spent in open versus closed arms, although
mobility was somewhat reduced in this test (Supplemen-
tal Fig. S2A,B). A 3-d learning paradigm on the accelerat-
ing rotarod revealed no significant difference compared
with wild-type animals (Supplemental Fig. S2C).
In contrast, mice homozygous for the Tau-Mecp2 allele
in the presence of the endogenous Mecp2 locus, which
were anticipated to express 3.8-fold more MeCP2 protein
than wild-type (1 + 1.4 + 1.4) were not recovered (Fig. 2D).
We expected ∼40 animals with this genotype among 159
progeny, but only two animals reached weaning, one of
which had to be culled due to a severely runted phenotype
and hydrocephalus. However, analysis of litters at 18.5 d
post-coitum (dpc) revealed the expected Mendelian pro-
portions of this genotype, indicating that death occurred
at or soon after birth (Fig. 2D). As this genotype results in
a Tau-null mouse, we wished to confirm that the pheno-
type was not due to lack of Tau. In line with previous
reports (Harada et al. 1994; Dawson et al. 2001), we
found that homozygous Tau-null mice were phenotypi-
cally normal, as weight, survival, and phenotypic score
(an aggregate score analyzing general appearance, activi-
ty, gait, tremor, breathing, and hindlimb clasping) were
indistinguishable from wild-type over 1 yr (Supplemen-
tal Fig. S2D–G).
Basis of MeCP2 overexpression toxicity
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Molecular analysis confirmed increased expression of
Tau-MeCP2 in the single surviving animal, as expected
(Supplemental Fig. S2H). In line with the reduced weight
observed in Tau-Mecp2 heterozygous animals, the Tau-
Mecp2 homozygous animal had even further decreased
weight (Supplemental Fig. S2I). It is notable that Tau-
Mecp2 homozygous mice lacking endogenous MeCP2
expression were recovered at normal Mendelian frequen-
cies. Thus, the combination of Tau deletion and 2.8-fold
MeCP2 overexpression does not lead to synthetic lethali-
ty, ruling out an interaction between these mutations
(Supplemental Fig. S2J). The results indicate that expres-
sion of MeCP2 in mice at ∼2.4–2.8 times the wild-type
level is unexpectedly benign, but ∼3.8 times the wild-
A
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Figure 1. MeCP2 is expressed from the Tau locus at wild-type levels in neurons and glia. (A) Schematic representation of the Tau-Mecp2
allele showing the intronic genomicDNAregion of theTau (Mapt) locus (blue bar), the loxP sites (green triangle), the 5′ extremity of exon 2
of Tau (black bar), the MeCP2 isoform e2 cDNA (red bar), the SV40 polyA signal (pink bar), and a selection cassette comprising the PGK
promoter, neomycin resistance gene, and PGK polyA signal (pale-green bar). Location of introducedmissensemutations (R133C, T158M,
and R306C) within MeCP2 are shown as vertical black lines. (B) Western blots of three brains of +/Tau-Mecp2 and wild-type littermates
(males, 7 wk) probed for MeCP2 and γ-tubulin. (C ) Quantification of B (mean and standard deviation). (Black bar) Wild-type; (orange bar)
Tau-MeCP2. Two-tailed unpaired t-test. n =3 for both genotypes.P =0.0005. (D) FACS analysis of nuclei expressingTau-MeCP2 inMeCP2
knockout background (pale orange) and wild-type (black) littermates. The histogram shows MeCP2 fluorescence intensity in the total
brain fraction, theNeuN-low fraction (mostly glia), and theNeuN-high fraction (mostly neurons) of nuclei. Shown are themean and stan-
dard deviation of three biological replicates. Two-tailed unpaired t-test. n =3 for both genotypes. P= 0.1853 total; P=0.0300 glia; P =0.0385
neurons. (E) Immunofluorescence of the hippocampus CA3 brain region of malemice (7 wk of age) with the following genotypes:Mecp2+/
y, Tau+/+ (wild type);Mecp2−/y, Tau+/+ (null); andMecp2−/y, Tau+/Tau-MeCP2 (Tau-MeCP2). Sections were stained for DAPI,MeCP2, and
NeuN. (F ) Survival of cohorts with the following genotypes: Mecp2−/y, Tau+/+ (gray line; n =14); Mecp2+/y, Tau+/+ (black line; n =9);
Mecp2−/y, Tau+/Tau-Mecp2 (pale-orange line; n =9); and Mecp2+/y, Tau+/Tau-Mecp2 (orange line; n=8). Each genotype was compared
with wild type using a Mantel-Cox test. P =0.4897 for Tau+/Tau-Mecp2, Mecp2+/y; P=0.3173 for Tau+/Tau-Mecp2, Mecp2−/y; P<
0.0001 for Tau+/+, Mecp2−/y. (G) Body weight of the mice shown in F (mean and standard deviation). As animals were dying during the
scoring period, repeated measures of ANOVA covering the entire time course was not possible. (H) Phenotypic score of the mice shown
in F. As animals were dying during the scoring period, repeated measures of ANOVA covering the entire time course was not possible.
Koerner et al.
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type level is severely toxic. The observed homozygous le-
thality in our model represented a more severe phenotype
than reported previously (Luikenhuis et al. 2004), which
may be due to differences in genetic background in this
mouse strain or husbandry differences.
Mutating the NID rescues the lethality caused byMeCP2
overexpression
We next asked whether mutations that cause Rett
syndrome alter toxicity when overexpressed in this sys-
tem. Initially, the relatively frequent mutation R306C,
which disrupts the interaction between MeCP2 and the
NCoR1/2 corepressor complexes, was introduced at the
Tau locus (Supplemental Fig. S3A,B). Heterozygous ex-
pression of this allele in mice deficient for endogenous
MeCP2 gave rise to typical features of Rett syndrome sim-
ilar to those observed when the endogenous locus is mu-
tated (Supplemental Fig. S3C–F; Lyst et al. 2013; Brown
et al. 2016). We noted that a double dose of the Tau-
Mecp2[R306C] allele in homozygotes on an Mecp2-null
background improved survival compared with heterozy-
gotes (Supplemental Fig. S3C). This argues that this muta-
tion retains weak MeCP2 function, in agreement with its
somewhat less severe phenotype in mice and humans
(Cuddapah et al. 2014; Brown et al. 2016). It is noticeable
that an increased dose of this hypomorphic allele im-
proved survival but not phenotypic scoring. Expression
of the Tau-Mecp2[R306C] allele in a wild-type back-
ground raised total MeCP2 to the same total abundance
as seen with wild-type Tau-Mecp2, reaching ∼3.6-fold in
Tau-Mecp2[R306C] homozygotes (Fig. 3A,B). Remark-
ably, in contrast to the neonatal lethal phenotype seen
with overexpressed wild-type MeCP2, mice expressing
transgenic R306C at the same high level were indistin-
guishable fromwild-type littermates (Fig. 3C–F). In the el-
evated plus maze, homozygous Tau-MeCP2[R306C]mice
showed normal avoidance of the open arms but modestly
reduced distance traveled during the test (Supplemental
Fig. S3G,H). The accelerating rotarod learning paradigm
also revealed no significant differences compared with
wild-type littermates (Supplemental Fig. S3I). We con-
clude that this single amino acid substitution effectively
abolishes the toxicity caused by MeCP2 overexpression.
Overexpressing MBD mutants in the presence of
wild-type MeCP2 causes neurological defects
We next performed the equivalent experiment with
mutations that affect DNA binding via the MBD. We first
introduced the most common missense Rett syndrome
mutation, T158M (which compromises DNA binding
but also reduces MeCP2 stability), into the Tau locus
(Supplemental Fig. S4A,B; Brown et al. 2016). As anticipat-
ed, mice heterozygous for the Tau-Mecp2[T158M] allele
that also lacked endogenous MeCP2 exhibited Rett
syndrome-like phenotypes similar in severity to equiva-
lent mutations at the endogenousMecp2 locus. Although
mice homozygous for the Tau-Mecp2[T158M] allele in
an Mecp2-null background showed improved survival
compared with Mecp2-null mice, phenotypic scoring
was not improved (Supplemental Fig. S4C–F; Brown
D
B CA
Figure 2. A 2.4-fold overexpression of MeCP2 is well tolerated, but 3.8-fold overexpression is lethal. (A) Survival of a cohort comprising
the following genotypes: +/+ (black line; n =8) and +/Tau-Mecp2 (orange line; n =8). (B) Body weight of the mice shown in A (mean and
standard deviation). Two-way repeated measures of ANOVA over the whole time course but excluding the animal that died were per-
formed. n =7 wild type; n =8 heterozygous. Genotype effect: F(1,13) = 102.7. P <0.0001. (C ) Phenotypic score of the mice shown in A.
Two-way repeated measures of ANOVA over the whole time course but excluding the animal that died were performed. n =7wild
type; n=8 heterozygous.Genotype effect: F(1,13) = 0.2809. P=0.6051. (D) Genotypes fromTau-Mecp2heterozygote intercrossings observed
at 18.5 d post-coitum (dpc) and atweaning. Genotypeswere +/+ (black bars), +/Tau-Mecp2 (orange bars), andTau-Mecp2/Tau-Mecp2 (dark-
red bars). Although homozyous animals were recovered at a Mendelian ratio at 18.5 dpc, only two homozygous animals were observed at
weaning (this is emphasized by the black arrow). One of those had to be culled due to hydrocephalus and severe runting; the second animal
survived >1 yr (see Supplemental Fig. S2D,E). A χ2 test was used to test for normal Mendelian ratios of genotypes. Embryonic day 18.5
(E18.5): χ2 = 2.646, P =0.2664; at weaning: χ2 = 39.58, P< 0.0001.
Basis of MeCP2 overexpression toxicity
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et al. 2016). Due to instability of the mutant protein, we
found that overexpression from the Tau-Mecp2[T158M]
locus led to only a modest increase in MeCP2 expression,
reaching ∼1.8 times wild type in Tau-Mecp2[T158M]
homozygotes in the presence of endogenous MeCP2
(Fig. 4A,B). This low level of additional mutant protein
did not severely affect survival or weight of mice, but
hindlimb clasping was strikingly elevated from ∼10 wk
of age, indicative of a significant brain pathology. Other
phenotypic aspects detected by weekly scoring were not
significantly altered (Fig. 4C–F; Supplemental Fig. S4G).
To determine whether MBD mutants consistently
caused overexpression phenotypes, we introduced the
R133C mutation into the Tau locus. R133C is another
common Rett syndrome mutation that also reduces
DNA binding and abundance of MeCP2, although less se-
verely than T158M (Supplemental Fig. S5A,B; Brown et al.
2016). As in the case of T158M,mice with the Tau-Mecp2
[R133C] allele in the absence of the endogenous Mecp2
gene mimicked the phenotype of an endogenous Mecp2
[R133C] allele (Supplemental Fig. S5C–F). Similar to the
previously published knock-in allele, heterozygous or
homozygous Tau-MeCP2[R133C] mice in an Mecp2-null
background showed improved survival compared with
Mecp2-null animals, but their phenotypic scores were
not improved. Mice homozygous for Tau-Mecp2[R133C]
in the presence of endogenouswild-typeMeCP2 expressed
wild type plus mutant proteins at 2.6 times wild-type and
were recovered at normal frequency atweaning (Fig. 4G–I).
Although this level of expression is similar to ∼2.4-fold
overexpression of wild-type protein in Tau-Mecp2 hetero-
zygotes, which have no obvious phenotype, we found that
excess R133C protein led to pronounced hindlimb clasp-
ing beyond∼6wkof age.These animals also displayed sub-
tly reduced body weight, although no significant effect on
survival was detected (Fig. 4J–L; Supplemental Fig. S5G).
Thus, when expressed in addition to wild-type MeCP2,
the toxicity observed previously for T158M commenced
earlier with the R133C mutation. We conclude that, in
contrast to overexpression of the R306C mutant protein,
which is benign even athigh levels, relativelymodestover-
expression of MeCP2 with missense MBDmutations in a
brain that additionally has normal levels of wild-type
MeCP2 is markedly deleterious.
The toxicity of MeCP2 overexpression is independent of
HDAC3 activity
Our finding that inactivation of the NID via an R306C
mutation abolishes the toxicity caused byMeCP2 overex-
pression focuses attention on the function of this do-
main. Previous evidence supports the hypothesis that its
primary role is to bind the TBL1X(R1) subunit and thereby
recruit NCoR corepressors (Lyst et al. 2013; Kruusvee
et al. 2017). A key shared subunit of NCoR1/2 complexes
is HDAC3 (You et al. 2013). HDAC3 is considered to
be the component of NCoR1/2 complexes that is respon-
sible for inhibiting transcription via deacetylation of
CA B
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Figure 3. A mutation in the NID renders high MeCP2 overexpression viable. (A) Western blots of three brains of animals heterozygous
and heterozygous for Tau-Mecp2[R306C] and of wild-type littermates (males, 7 wk) probed forMeCP2 and γ-tubulin. (B) Quantification of
Western blots shown in A (mean and standard deviation). (Black) +/+; (light purple) +/Tau-Mecp2[R306C]; (dark purple) Tau-Mecp2
[R306C]/Tau-Mecp2[R306C]. Two-tailed unpaired t-test. n =3 for each genotype. P =0.0020 for wild type versus heterozygous;
P= 0.0005 for wild type versus homozygous. (C ) Genotype distribution from Tau-Mecp2[R306C] heterozygous intercrossings observed
at weaning. Legend is as for B. A χ2 test was used to test for normal Mendelian ratios of genotypes. P =0.7258. (D) Survival of a cohort
comprising +/+ (n =9), +/Tau-Mecp2[R306C] (n =9), and Tau-Mecp2[R306C]/Tau-Mecp2[R306C] (n=9). (E) Body weights of the mice
shown inD (mean and standard deviation). Two-way repeatedmeasures of ANOVA (excluding onewild-type and one homozygous animal
that died) were performed. n =8wild type; n =9 heterozygous; n=8 homozygous. Genotype effect: F(2,22) = 5.807. P=0.0094. (F ) Phenotypic
score of the mice shown in D. Two-way repeated measures of ANOVA (excluding one wild-type and one homozygous animal that died)
were performed. n =8 wild type; n =9 heterozygous; n=8 heterozygous. Genotype effect: F(2,22) = 0.309. P =0.7373.
Koerner et al.
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Figure 4. Overexpression ofMBDmutants in addition towild-typeMeCP2 is deleterious. (A)Western blots of three brains of animals het-
erozygous and homozygous for Tau-Mecp2[T158M] and wild-type littermates (males, 7 wk) probed for MeCP2 and γ-tubulin. (B) Quanti-
fication of blots shown inA (mean and standard deviation). Genotypes are +/+ (black), +/Tau-Mecp2[T158M] (light green), and Tau-Mecp2
[T158M]/Tau-Mecp2[T158M] (dark green). A two-tailed unpaired t-testwas used for statistical analysis.P =0.0748 forwild type versus het-
erozygous; P =0.0053 for wild type versus homozygous. (C ) Genotypes derived from Tau-Mecp2[T158M] heterozygous intercrossings ob-
served at weaning. A χ2 test was used to test for normal Mendelian ratios of genotypes. P =0.1554. (D) Survival of a cohort comprising +/+
(black;n=9), +/Tau-MeCP2[T158M] (bright green; n=10), andTau-Mecp2[T158M]/Tau-Mecp2[T158M] (dark green;n= 10). AMantel-Cox
test was used to analyze survival. P =0.5767 for wild type versus heterozygous; P=0.2918 for wild type versus homozygous. (E) Body
weights of the mice shown in D (mean and standard deviation). Two-way repeated measures of ANOVA were performed (weeks 3 and
40 were excluded, as not all animals were analyzed; one wild-type and two heterozygous animals that died were also excluded). n =8
wild type; n =8 heterozygous; n =10 homozygous. Genotype effect: F(2,23) = 0.3047. P=0.7403. (F ) Clasping score of the mice shown in
D. Two-way repeated measures of ANOVA were performed (weeks 3 and 40 were excluded, as not all animals were analyzed; one wild-
type and two heterozygous animals that diedwere also excluded). n =8wild type; n=8 heterozygous; n=10 homozygous. Genotype effect:
F(2,23) = 4.964. P= 0.0161. Overall scores are in Supplemental Figure S4G. (G) Western blots of three brains of mice heterozygous and
homozygous for Tau-Mecp2[R133C] and wild-type littermates (males, 7 wk) probed for MeCP2 and γ-tubulin. (H) Quantification of blots
shown in G (mean and standard deviation). The genotypes used were +/+ (black), +/Tau-Mecp2[R133C] (cyan), and Tau-Mecp2[R133C]/
Tau-Mecp2[R133C] (dark blue). A two-tailed unpaired t-test was used for statistical analysis. P =0.0028 for wild type versus heterozygous;
P=0.0002 forwild type versus homozygous. (I ) Genotypes resulting fromTau-Mecp2[R133C]heterozygote intercrosses observed atwean-
ing. Legend is as forH. A χ2 testwas used to test for normalMendelian ratios of genotypes. P=0.6256. (J) Survival of a cohort comprising +/+
(black; n =11), +/Tau-Mecp2[R133C] (cyan; n =10), and Tau-Mecp2[R133C]/Tau-Mecp2[R133C] (dark blue; n =12). This was analyzed
using a Mantel-Cox test. P= 0.2943 for wild type versus heterozygous; P =0.1560 for wild type versus homozygous. (K ) Body weights of
the mice shown in J (mean and standard deviation). Two-way repeated measures of ANOVA were performed (week 3 was excluded as
not all animals were analyzed; one heterozygous and three homozygous animals that died were also excluded). n= 11 wild type; n =9 het-
erozygous; n =9 homozygous. Genotype effect: F(2,26) = 5.937. P =0.0075. (L) Clasping score of themice shown in J. Two-way repeatedmea-
sures ofANOVAwere performed (week3was excluded, as not all animalswere analyzed; oneheterozygous and three homozygous animals
that died were also excluded). n =11 wild type; n =9 heterozygous; n =9 homozygous. Genotype effect: F(2,26) = 16.6. P< 0.0001.
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histones. To determine geneticallywhether the activity of
HDAC3 mediates the toxic effects of MeCP2 overexpres-
sion, we used mutants in NCoR1 and NCoR2 proteins
that reduce HDAC3 catalytic activity (Fig. 5A; You et al.
2013). HDAC3 is catalytically inactive in isolation but be-
comes active upon interaction with the DADs of NCoR1
and NCoR2 proteins (Guenther et al. 2001; You et al.
2013). The DAD mutations in NCoR1/2 greatly reduce
HDAC3 activation, but the reported phenotype of homo-
zygous double mutants (NS-DAD mutants) is mild with-
out overt neurological abnormalities (You et al. 2013).
If HDAC3 activity within the NCoR1/2 complexes is
the primary downstream effector of MeCP2, these mice
should at a minimum exhibit Rett syndrome-like features
but in fact are viable with normal survival. As HDAC3-
null mutations are embryonically lethal, we considered
the possibility that DAD mutations retain some HDAC3
activity. We recovered NCoR1/2 complexes from brain
extracts using affinity for a NID peptide and found that
HDAC3 was retrieved equally from wild-type and NS-
DAD mutant extracts, indicating no detectable effect of
the mutations on the binding of HDAC3 to NCoR1 or
NCoR2 complexes (Fig. 5B). However, the amount of re-
covered HDAC activity was drastically reduced in NS-
DAD mutant brains (Fig. 5C). We conclude that the
DADmutations significantly reduce HDAC activity asso-
ciated with NCoR complexes by >70%.
The finding that the DAD mutations show severely
reduced HDAC activity made it possible to test whether
the toxicity caused byMeCP2 overexpression is due to ex-
cessive HDAC3 activity. According to this hypothesis,
DADmutationswould be expected to significantly reduce
the severity of this phenotype. The experiment requires
MeCP2 overexpression in mice that are homozygous for
knock-in DAD mutations in both NCoR1 and NCoR2.
Despite the reduced ability of the DAD mutant corepres-
sors to activate HDAC3, we observed no discernible im-
provement in the early lethal phenotype resulting from
MeCP2 overexpression (Fig. 5D; Supplemental Fig. S6A).
Therefore, in contrast to overexpression of the R306Cmu-
tant, which resulted in effectively wild-type mice, the
inability of NCoR1/2 to fully activate HDAC3 did not
ameliorate the overexpression phenotype. Our results
suggest that while toxicity very likely requires excessive
TBL1XR1 and hence NCoR1/2 complex recruitment, it
does not depend on HDAC3 activity.
Discussion
A goal of the present work was to determine which do-
mains of the MeCP2 protein underlie the severe pheno-
type caused by its overexpression. To achieve this, we
drove transcription of an MeCP2 cDNA from the endoge-
nous Tau locus in mice that also expressed the X-linked
wild-type gene. Levels of Tau-MeCP2 closely mimicked
those of endogenous MeCP2 in both neurons and glia.
In agreement with a previous report (Luikenhuis et al.
2004), mice with only Tau-MeCP2 as a source of MeCP2
protein were viable, fertile, and overtly normal in
A
B C
D
Figure 5. Reducing HDAC3 activity does not rescue lethality of
Tau-Mecp2 overexpression. (A) Schematic overview of the exper-
iment. In wild-type brains, MeCP2 (red cylinder) recruits the
core NCoR1/2 complexes (green circles) by binding to TBL1X
(R1) (bright-green circle). If the NID of MeCP2 is mutated
(R306C), MeCP2 cannot bind and recruit the NCoR complexes.
In NS-DAD mutants, the mutated DADs of both NCoR1 and
NCoR2 fail to fully activateHDAC3, allowing removal of histone
acetyl groups. (B) An MeCP2 peptide containing either the wild-
type or a mutated (R306C) NID was used to pull down TBL1XR1
and HDAC3 from brain nuclear extracts from wild-type or NS-
DAD animals. Wild-type MeCP2 pulls down NCoR1/2 compo-
nents from both wild-type andNS-DAD brain extracts with simi-
lar efficiency, whereas the R306C peptide is unable to pull down
the corepressor subunits from either extract. (C ) Proteins isolated
in B were assayed for HDAC activity. Shown are mean and stan-
dard deviation of three biological replicates as well as background
luminescence readings. HDAC activity of proteins pulled down
using an MeCP2 wild-type peptide from NS-DAD brains is re-
duced to ∼27% of wild-type brains. The R306C peptide recovered
∼5%HDAC activity irrespective of brain genotype. (D) The num-
berof animals surviving toweaningwhenwild-type,heterozygous
or homozygous forTau-Mecp2, and either heterozygous or homo-
zygous forN-DAD and S-DADmutations. The failure of animals
homozygous for Tau-Mecp2 to survive was not rescued by reduc-
ing HDAC3 activity via DAD mutations either singly or on both
NCoR1andNCoR2. For survival of additional genotypes, see Sup-
plemental FigureS6A.Note that asNcorandTaugenesare located
on the same chromosome (42Mb apart), +/Tau-Mecp2 is observed
at a reduced frequency if N-DAD is homozygous (43 cM). A χ2
test was used to test for normal Mendelian ratio of genotypes.
P<0.0001 for homozygous–heterozygous; P=0.0001 for hetero-
zygous–homozygous; P=0.0025 for homozygous–homozygous,
indicating a non-Mendelian distribution.
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phenotype despite lacking the native promoter and the
unusually long (∼8.5-kb) 3′ untranslated region that is an
evolutionarily conserved feature of the endogenous tran-
script (Singh et al. 2008). When this autosomal transgene
was expressed heterozygously in mice with an endoge-
nousMecp2 gene, animals were also phenotypically rela-
tively normal despite a 2.4-fold increase in brain MeCP2
(Supplemental Fig. S6B). The results raise the possibility
that mice are more tolerant than humans to MeCP2 over-
expression. It was reported previously that expression of
the human MECP2 locus in mice with normal levels of
the endogenous protein also leads to a relativelymild phe-
notype, although survival andmotor function are compro-
mised to a somewhat greater extent than seen here
(Collins et al. 2004). The difference may be due to the al-
tered genetic background or brain region-specific expres-
sion in those experiments.
A recent study provided evidence that twofold overex-
pression of MeCP2 carrying either the R306C mutation,
which abolishes NID function, or the R111G mutation,
which abolishes binding to methylated DNA, is pheno-
typically neutral (Heckman et al. 2014). The severe
phenotype caused by higher expression of Tau-MeCP2
provides a more stringent test of the toxicity of mutant
MeCP2 overexpression. Using this approach, we establish
here that ∼3.6-fold overexpression of MeCP2[R306C]
leads to a wild-type phenotype, in stark contrast to the le-
thal phenotype caused by equivalent levels of wild-type
MeCP2 (Supplemental Fig. S6B). It follows that toxicity
is intimately dependent on excess of this domain, whose
only well-characterized function is to bind the WD40
domain of TBL1X and its close relative, TBL1XR1. Indeed,
a recent crystal structure of the NID bound to the
TBL1XR1 subunit, which is shared byNCoR1/2 complex-
es, showed that four adjacent amino acids that are individ-
ually mutated in Rett syndrome (one of which is R306)
all make intimate molecular contacts with the WD40
domain of TBL1XR1 (Kruusvee et al. 2017). Our data sug-
gest that the MeCP2–TBL1X(R1) interaction, which is
critical for avoidance of Rett syndrome, is also of pivotal
importance as a cause of MECP2 duplication syndrome.
It seems that Rett syndrome is caused by too little recruit-
ment of TBL1X(R1) to DNA, whereas inMECP2 duplica-
tion syndrome, TBL1X(R1) recruitment is excessive.
TBL1X(R1) proteins are best known as components of
the NCoR1/2 corepressor complexes, where they form
a tetramer that associates with the NCoR scaffolds
(Oberoi et al. 2011). AsMeCP2 pulls downmajor subunits
of NCoR1/2 complexes by immunoprecipitation (Lyst
et al. 2013), we infer that the primary consequence of
interaction with TBL1X(R1) is recruitment of these core-
pressors. While it is conceivable that TBL1X(R1) is in-
volved in additional functional complexes that are
relevant to Rett syndrome, none has so far been charac-
terized. We therefore sought to establish what features
of NCoR1/2 might account for toxicity. The primary me-
diator of transcriptional inhibition by NCoR corepressors
is thought to be histone deacetylation via HDAC3, which
is inactive unless intimately associated with these com-
plexes (Guenther et al. 2001; You et al. 2013). In view of
evidence that occupancy of gene bodies by MeCP2 in
vivo correlates positively with relative down-regulation
of gene expression (Kinde et al. 2016; Lagger et al. 2017),
an attractive possibility was that this effect is mediated
through histone deacetylation by HDAC3. Based on our
evidence that hyperrecruitment of TBL1X(R1) underlies
the MeCP2 overexpression phenotype, it follows that
reducing HDAC3 activity associated with NCoR1/2 com-
plexes might ameliorate this phenotype. Strikingly,
though, we saw no reduction in the severe consequences
of Tau-MeCP2 overexpression in NS-DAD mice. Al-
though absence of a genetic rescue must be interpreted
with caution, the fact that DAD mutations in both
NCoR1 and NCoR2 (You et al. 2013) reduced MeCP2-
associated HDAC activity by ∼72% (Fig. 5C) strongly sug-
gests that the MeCP2 overexpression phenotype is inde-
pendent of HDAC3 activity. It is likely that even a small
reduction in severity would have been detected in this
experiment, as MeCP2-overexpressing mice are born but
fail to survive until weaning. For example, our Tau-
Mecp2 homozygous mice on a wild-type background
(total of 3.8-fold overexpression) fail to survive until wean-
ing, whereas Tau-Mecp2 homozygous mice on a Mecp2-
null background (2.8-fold overexpression) were recovered
at Mendelian ratios (Fig. 2D; Supplemental Fig. S2J). The
finding that this ∼26% reduction in MeCP2 dosage is suf-
ficient for a striking improvement in phenotypic outcome
suggests that the phenotype is sensitive enough to detect
subtle decreases in the level ofMeCP2 functionality. Tak-
en together, the results lead us to conclude that HDAC3
activity does not play a major part in MeCP2 toxicity. It
follows that inhibitors of HDAC3 are unlikely to be ther-
apeutically useful for treatment of MECP2 duplication
syndrome. An alternative strategy might be to inhibit
the interaction of MeCP2 with NCoR1/2 complexes
themselves using small molecules.
Assuming that the interaction between MeCP2 and
TBL1X(R1) predominantly recruits NCoR1/2, we may
ask what other features of these corepressors might be re-
sponsible for the adverse phenotype. Interestingly, the
HDAC3 protein itself has been reported to affect tran-
scription in a deacetylation-independent manner (Sun
et al. 2013), which probably would not be affected by the
DAD mutations. Also, it is possible that other enzymes,
notably class IIa HDACs, associate with NCoR either
directly or indirectly and cause deacetylation (Fischle
et al. 2001; Fischle et al. 2002; Hudson et al. 2015). A fur-
ther possibility is that the large NCoR1/2 complexes have
other functions that mediate the deleterious consequenc-
es of overrecruitment. These could include recruiting ac-
tivities such as the ubiquitin protease USP44 (Lan et al.
2016) or the ubiquitin-conjugating enzyme UbcH5 (Peri-
ssi et al. 2004). Distinguishing these possibilities is a pri-
ority for future work.
UnlikeMeCP2[R306C] overexpression, which was phe-
notypically neutral, mild overexpression of Rett syn-
drome-causing MBDmutants on top of wild-type MeCP2
was detrimental. Both T158M and R133C mutations are
defective in DNA binding but also somewhat unstable.
To our knowledge, all MBD mutants of MeCP2 reported
Basis of MeCP2 overexpression toxicity
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so far are unstable to varying degrees. Because of this,
overexpression did not yield the high levels seen with
wild-type or R306C mutant proteins. Despite very mild
overexpression, we observed a strong hindlimb-clasping
phenotype in each case, indicative of pathologies affecting
the brain and/or spinal cord (Lalonde and Strazielle 2011).
The toxic effect was stronger in the case of R133C, which
retains more DNA-binding affinity, is more stable than
T158M, and gave ∼2.6 times wild-type levels of total
MeCP2 in brain. In contrast, animals expressing equiva-
lent levels of wild-type protein (2.4 times wild type)
were phenotypically normal apart from reduced weight.
These findings raise the possibility that overexpression
of a protein that cannot effectively bindDNA causes dom-
inant-negative effects. In this connection, it may be rele-
vant that both of these proteins contain an intact NID,
which may still be available to interact with NCoR1/2.
A previous study using a different MBD mutation,
R111G, expressed on top of wild-type MeCP2 led to a dif-
ferent conclusion, as no adverse phenotype was observed
(Heckman et al. 2014). The disparity is unexplained but
may be due to differences in genetic background, the alter-
nativemutants that were analyzed, or the nonoverlapping
assay paradigms used in the two cases. Whether the toxic-
ity of MBDmutatedMeCP2 requires HDAC3 activity has
yet to be formally tested, although we consider this un-
likely given thatwild-typeMeCP2 appears not to function
via this pathway.
A separate study suggested that overexpression of
T158M in anMecp2-null background ameliorated pheno-
typic severity and may therefore offer a potential thera-
peutic strategy for Rett syndrome (Lamonica et al. 2017).
Due to the instability of the mutant protein, the risk of
toxicity caused byMeCP2 overexpression would arguably
be reduced. Our results cast doubt on the validity of this
approach, as mice expressing a combination of wild-type
and mutant protein were adversely affected compared
with mice expressing the same level of only wild-type
MeCP2. As the Rett syndrome brain is mosaic for func-
tionally wild-type and mutant cells, there is a risk that
delivery of excess T158M or R133C mutant proteins
would cause toxic side effects. Another concern raised
by these results is that future gene therapy in which
wild-type MeCP2 would be introduced into neurons ex-
pressing anMBDmutant form (e.g., T158M)wouldmimic
the protein combination that gives a hindlimb-clasping
phenotype in our study. Further workwithmodel systems
is needed to determine whether gene therapy for individ-
uals with MBDmutations might carry a risk and whether
this would be outweighed by clinical benefit.
Materials and methods
Generation of knockout embryonic stem cells and mice
The targeting vector containing a homology region around Tau
exon 2 and an in-frame insertion ofMecp2 cDNA (e2 isoform) af-
ter the first 31 amino acids of theTau-coding sequence (a gift from
Dr Rudolf Jaenisch) (Luikenhuis et al. 2004) was modified in the
following way: To introduce the 3′ loxP site, a neomycin resis-
tance cassette driven by a hybrid PGK-EM7 promoter with an up-
stream loxP site fromPL452 (Liu et al. 2003) replaced the previous
neomycin resistance cassette by recombineering. The 5′ loxP site
was inserted by standard cloning of a loxP-containing oligo into
the BplI site upstream of Tau exon 2. The 5′ homology arm was
extended by integrating a KpnI fragment (mm9: chromosome
11: 104,142,690–104,143,022) obtained by PCR from E14 Tg2a
embryonic stem cell DNA. To integrate point mutations within
Mecp2 (T158M, R133C, and R306C), the QuikChange II XL
site-directed mutagenesis kit (Stratagene, 200521) was used
(primers: R306C-S [TCCCCATCAAGAAGTGCAAGACCCGG
GAG], R306C-AS [CTCCCGGGTCTTGCACTTCTTGATGGG
GA], R133C-S [CCAGGGAAAAGCTTTTTGCTCTAAAGTA
GAATTG], R133C-AS [CAATTCTACTTTAGAGCAAAAAGC
TTTTCCCTGG], T158M-S [GGACCCTAATGATTTTGACTT
CATGGTAACTGGGAGAG], and T158M-AS [CTCTCCCAGT
TACCATGAAGTCAAAATCATTAGGGTCC]). The targeting
vector was linearized using SacII before electroporation. Electro-
poration of the targeting vectors and neomycin selection were
performed using standard conditions in E14Tg2a (129P2/OlaHsd)
embryonic stem cells. Embryonic stem cells were grown in Glas-
gow MEM (Gibco) supplemented with 10% FBS (batch tested)
(Gibco), 1% nonessential amino acids (Gibco), 1% sodium pyru-
vate (Gibco), 0.1% β-mercaptoethanol (Gibco), and 1000 U/mL
LIF (ESGRO). Positive embryonic stem cell clones were identified
by Southern blot screening and PCR fragment sequencing confir-
mation. They were injected into C57BL/6JOla blastocysts and
transferred into pseudo-pregnant recipient mice. Transgenic off-
spring were backcrossed onto C57BL/6JOla or crossed with
Mecp2-null animals on a C57BL/6JOla ×CBA F1 background for
further experiments. Tau knockout mice were generated by mat-
ing Tau-Mecp2 mice with CMV-CRE mice (JAX, 006054) to
delete the sequence in between the two loxP sites.
All mice used in this study were bred and maintained at the
University of Edinburgh animal facility under standard condi-
tions, and procedures were carried out by staff licensed by the
UK Home Office and in accordance with the Animal and Scien-
tific Procedures Act 1986. Transgenicmice were caged with their
wild-type littermates.
Biochemical analysis
Brains (usually at 6–8 wk of age) were harvested by snap-freezing
in liquid nitrogen. DNA isolation was performed by overnight in-
cubation in 1× TEN (50 mM Tris at pH 9.0, 20 mM EDTA at pH
8.0, 40 mMNaCl, 1% SDS, 0.5 mg/mL proteinase K) at 55°C fol-
lowed by high-salt extraction and precipitation using isopropanol.
For Southern blots, 10- to 20-µg aliquots of genomic DNA were
digested overnight with 2 U/µg suitable restriction enzyme and
separated by gel electrophoresis on 0.8% agarose gels and 1×
TBE at 5.3 V/cm. The gel was denatured twice for 30min in dena-
turing solution (0.5 M NaOH, 1.5 M NaCl) and blotted for at
least 18 h onto Hybond-XL nylon membranes (GE Healthcare)
in denaturing solution. After neutralization of the membrane in
20 mM Na2HPO4, the membrane was prehybridized in Church
buffer (0.25M Na2HPO4, 7% SDS, 1 mM EDTA) for 30 min at
65°C followed by hybridization with radioactive probes in
Church buffer for at least 18 h at 65°C. Probes (Tau-P3: chromo-
some 11: 104,148,301–104,149,009; Tau-P4: chromosome 11:
104,142,739–104,143,549) were labeled using the Prime-a-Gene
labeling system (Promega, U1100) with α32-dCTP. Blots were
washed twice for 30 min in Church wash (1% SDS, 20 mM
Na2HPO4) and exposed overnight to phosphorimager plates.
Plates were scanned using a Typhoon FLA 9500 (GE Healthcare).
Brain nuclear extracts were prepared as described previously
(Lyst et al. 2013). HDAC3-containing complexes were isolated
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using a biotin-tagged MeCP2-derived peptide (residues 285–313)
immobilized on streptavidin sepharose (GE Healthcare) as de-
scribed previously (Lyst et al. 2013). Bound proteins were ana-
lyzed by SDS-PAGE followed by Western blotting or by using
theHDAC-Glo(TM) I/II assay and screening system (Promega) ac-
cording to the manufacturer’s instructions.
Flow cytometry analysis was performed as described previous-
ly (Tillotson et al. 2017) using a NeuN antibody conjugated to
AF488 (Millipore, MAB377X) and an MeCP2 antibody (Sigma,
M6818) conjugated to AF647 (APEX antibody labeling kit, Invi-
trogen, A10475). For the immunofluorescent stainings, mouse
brains were hemisected and rapidly frozen by immersion in iso-
pentane chilled on dry ice. A Leica CM1900 cryostat was used
to cut 10-µm parasagittal sections, which were mounted on
SuperFrost Plus slides (VWR) and stored at −80°C prior to stain-
ing. Slides for staining were allowed to dry for 10 min at room
temperature, fixed in a 1:1 methanol:actetone mixture at −20°
C for 20min, and then dried for 5min at room temperature. After
two 10-min washes in PBS, sections were blocked for 1 h in 1.5%
normal goat serum (Sigma) in PBS (blocking buffer) at room tem-
perature in a humidified chamber. The following primary anti-
bodies were incubated overnight at 4°C: anti-MeCP2 rabbit
monoclonal D4F3 (Cell Signalling Technology) and anti-NeuN
Cy3-labeled mouse monoclonal A60 (EMD Millipore Corp.),
both diluted 1:200 in blocking buffer. Sections were washed as
described previously and then incubated with a biotinylated
anti-rabbit secondary antibody (Vector Laboratories) diluted
1:200 in blocking buffer for 1.5 h at room temperature. After
washing again, sections were incubated with avidin-FITC (Vector
Laboratories) diluted 1:200 in 10 mM HEPES and 150 mM NaCl
for 20min at room temperature. Sectionswere thenwashed three
times for 10 min in PBS, with the first wash including 1 µg/mL
DAPI. They were then mounted in ProLong Gold (Life Technol-
ogies), left to cure in the dark overnight at room temperature,
and then stored at 4°C. Stained sections were imaged on a Leica
SP5 confocal microscope using a 63× objective, keeping all set-
tings the same between samples (apart from R133C and T158M
high-exposure images, where the gain was increased [by the
same amount] for the FITC channel to visualize the low levels
of MeCP2).
Phenotypic characterization of mice
Male mice on a mixed background from the age of 3–4 wk until
36–52 wk were subjected to a weekly scoring and weighing re-
gime as described in Brown et al. (2016). Animals that are de-
scribed to having “died” in most instances were culled having
reached one of the end points as set out in the Home Office Pro-
ject Licence. For behavioral analysis using the elevated plusmaze
and the accelerating rotarod, micewere backcrossed onto C57BL/
6JOla for seven generations and analyzed blind to genotype.
Males aged 19–20 wk were used for these experiments as de-
scribed in Brown et al. (2016).
Statistical analysis
Statistical tests appropriate to the nature of the data were carried
out usingGraphpad Prism.The death of animals that needed to be
culled during the course of the study due to phenotype-unrelated
causes (injuries caused by fighting) was censored in the survival
analysis. This is indicated by small vertical ticks in the survival
curves. To allow analysis by two-way repeated measures of
ANOVA on weight and phenotypic scoring data sets where a
small number of animals had died during the study, these animals
were removed from the analysis. Similarly, weeks when it was
not possible to score all of the animals were also removed from
the analysis.
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